Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

603 results about "Sulfonilamide" patented technology

Method for preparing bi-(sulfonyl fluoride) imine and (fluorinated alkyl sulfonyl fluorine sulfonyl) imine alkali metal salt

The invention discloses a method for preparing bi-(sulfonyl fluoride) imine and (fluorinated alkyl sulfonyl fluorine sulfonyl) imine alkali metal salt. The method comprises the following steps of: reacting sulfamide and thionyl chloride and chlorosulfonic acid to prepare bi-(sulfonyl chlorine) imine and (fluorinated alkyl sulfonyl chlorine sulfonyl) imine, reacting with antimony trifluoride and potassium carbonate (rubidium or caesium) to obtain corresponding high-purity bi-(sulfonyl fluoride) imine potassium (rubidium or caesium) salt or (fluorinated alkyl sulfonyl fluorine sulfonyl) imine potassium (rubidium or caesium) salt, performing double decomposition exchange reaction using the potassium (rubidium or caesium) salt with the lithium perchlorate (or sodium) or lithium tetrafluoroborate (or sodium) in the aprotic polar solvent to obtain corresponding lithium (or sodium) salt with high purity. The method in the invention has the characteristics of simple operating steps, easy separation and extraction of output, high purity and yield, no environmental pollution, and the like, and is suitable for mass industrial production.
Owner:武汉市瑞华新能源科技有限公司

Pyridyl sulfonamides as modulators of ion channels

InactiveUS20090105271A1Lessen severityBiocideNervous disorderIonMedicinal chemistry
The present invention relates to pyridyl sulfonamide derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Owner:VERTEX PHARMA INC

Chiral sulfinylamine monophosphine, and full-configuration preparation method and application thereof

The invention provides a chiral sulfinylamine monophosphine and a preparation method thereof. The preparation method comprises the following steps: carrying out a condensation reaction of 2-disubstituted phosphinoaryl(heteroaryl)formaldehyde (ketone) 2 and chiral sulfonamide 3 to obtain a compound 4, and reacting the compound 4 with a nucleophilic reagent to prepare a compound 1; or carrying out a condensation reaction of aldehyde (ketone) 5 and the chiral sulfonamide 3 to obtain imine 6, and reacting the imine 6 with a 2-disubstituted phosphinoaryl(heteroaryl) metal reagent to obtain the compound 1; or reacting the imine 6 with the 2-disubstituted phosphinoaryl(heteroaryl) metal reagent to obtain a compound, and reducing the compound to obtain the compound 1; or carrying out a condensation reaction of 2-substituted phosphinoaryl(heteroaryl)formaldehyde (ketone) 8 and the chiral sulfonamide 3 to obtain an imine compound 9, reacting the imine compound 9 with the nucleophilic reagent to obtain a compound 7, and reducing the compound 7 to obtain the compound 1. Different chiral sulfenamides and different metal reagents are used to conveniently obtain the optically pure compound of four configurations comprising (R,R), (R,S), (S,S) and (S,R). The above ligand has the advantages of simple skeleton, synthesis convenience and easy reconstruction, can be applied in various metal-catalyzed asymmetric reactions, and has a very high reaction activity and stereoselectivity.
Owner:苏州凯若利新材料科技有限公司

Anti-tumor medicine in double-aryl urea structure based on indazole, indole, azaindazole or azaindole

The invention belongs to the field of medicines, relates to anti-tumor medicines, and in particular relates to anti-tumor medicines in double-aryl urea structures based on indazole, indole, azaindazole or azaindole. The structural formulae of the anti-tumor medicines are shown in formula (Ia) and formula (Ib), wherein Z is N atom or C atom; W is O; M is O, S, N or CH; n is 1 or 2; Y and R are halogen atoms, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxyl group, ester group, cyano group, mercapto group, alkyl sulphanyl, sulfuryl, sulfoxide, sulfonic group, sulfamate, sulfonamide, ketonic group, aldehyde group, nitro group or nitroso group. Pharmacodynamic experiments prove that the medicines have good anti-tumor effects on human lung cancer, human kidney cancer, human colon cancer, human liver cancer, human gastric cancer, human breast cancer, melanoma and the like.
Owner:JINAN HAILE MEDICAL TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products